fashion -WSS

fashion

author：knowledge 2025-10-01 15:28:24 - browse：51

DENVER — He could have been a rock star, a religious icon, the way ecstatic applause from thousands of attendees greeted the man dressed in a crisp, all-white suit as he strode onto a backlit stage. He was neither. This was Rick Doblin, the founder and evangelist of a movement to legalize psychedelic MDMA and bring the drug into mainstream medicine.

The scene in a Denver conference hall last week was a world away from the first conference Multidisciplinary Association for Psychedelic Studies (MAPS) held in 1990, when Doblin spoke alongside Timothy Leary — the ex-Harvard professor who popularized the phrase “turn on, tune in, and drop out.” That was just a few years after MDMA, also known as ecstasy, was criminalized, deemed a Schedule 1 drug “of no medical use.”

Now, as MAPS nears its goal of winning Food and Drug Administration approval for MDMA as a treatment for post-traumatic stress disorder, the perpetually smiling and energetic Doblin is basking in the adoration from both legions of “psychonauts” and unlikely yet powerful allies. “I literally love Rick Doblin,” the conservative Republican and former Texas governor Rick Perry told the audience in Denver.

It was a seemingly triumphant occasion. But even as Doblin is in sniffing distance of his lifelong quest, his once counter-cultural organization is grappling with the pressures of having to operate in the capitalist pharmaceutical sphere. MAPS was founded in 1986 as a nonprofit with deep-seated ideals. Doblin developed an “anti-patent” strategy, putting discoveries in the public domain so they couldn’t be claimed as intellectual property. He raised money to fund clinical trials of MDMA from like-minded wealthy donors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Readout Newsletter: Bristol, Sangamo, Gilead, and more

hotspot

WSS

After decades in use, heart stents finally beat placebo

How state and local governments are sidelining science

What is STAT's opinion section for?

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

After decades in use, heart stents finally beat placebo

Readout Newsletter: CAR

Wikipedia

fashion

knowledge

The cancer drug shortage isn’t new — and neither are the solutions

Change Healthcare outage fallout shows need for new oversight

How to save PrEP access — and even expand it

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Apple is now the first public company to be valued at $3 trillion

Ebola: Gilead Sciences antiviral shows promise as new treatment

As demand for Covid shots wanes, Moderna seeks its next success

As AI in medicine takes off, can 'human in the loop' prevent harm?

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Ebola: Gilead Sciences antiviral shows promise as new treatment

leisure time

Ohio still needs to do more to protect the right to abortion

Carbon Health diabetes program, a test of data

Steward Health Care Massachusetts hospitals face fiscal disaster

President Biden's budget: Here's what you might have missed

EPA limits use of carcinogenic gas for sterilizing medical devices

Study suggests Covid rebound is far more common with Paxlovid than without

focus

explore

hotspot

knowledge